BresMed

BresMed was established in 2006, and now has over 100 staff in the UK, the Netherlands, Denmark, Ireland and India. We are an independent health economic and outcomes research (HEOR) consultancy.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

ARS PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM WITH ADDITION OF PHARMACEUTICAL COMMERCIALIZATION VETERANS

ARS Pharmaceuticals, Inc. | February 10, 2022

news image

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive vice president, commercial strategy and Daniel Relovsky as senior vice president, sales and marketing. Mr. Kaplan and Mr. Relovsky, accomplished industry veterans with proven track r...

Read More

MAJOR PHARMA COMPANIES INCLUDING NOVARTIS AND MERCK BUILD FEDERATED LEARNING PLATFORM FOR DRUG DISCOVERY

Venturebeat | September 17, 2020

news image

Last June, 10 major pharmaceutical companies — Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). In partnership with Nvidia, Owkin, and other tech partners, the group sought to leverage techniques like federated learning to collectively train AI on datasets without having to share any pro...

Read More

PREPARATION PRODUCTS OF YILING PHARMA APPROVED BY FDA FOR LAUNCH IN THE US MARKET

Yiling Pharmaceutical Co | September 19, 2020

news image

Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter referred to as the "FDA"), which were submitted by Yiling Wanzhou International Pharmaceutical Co., Ltd., one of the wholly-owned subsidiaries of Yiling Pharmaceutical Co., Ltd., meaning that these products are approved to be produced and sold i...

Read More

U.S. FDA ACCEPTS BIOHAVEN'S SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) OF NURTEC™ ODT FOR THE PREVENTIVE TREATMENT OF MIGRAINE

Biohaven Pharmaceutical Holding Company Ltd. | October 14, 2020

news image

Biohaven Pharmaceutical Holding Company Ltd. today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) goal date for completion of the FDA review of the preventive sNDA is set for 2Q2021. Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "Patients with mi...

Read More
news image

BUSINESS INSIGHTS

ARS PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM WITH ADDITION OF PHARMACEUTICAL COMMERCIALIZATION VETERANS

ARS Pharmaceuticals, Inc. | February 10, 2022

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive vice president, commercial strategy and Daniel Relovsky as senior vice president, sales and marketing. Mr. Kaplan and Mr. Relovsky, accomplished industry veterans with proven track r...

Read More
news image

MAJOR PHARMA COMPANIES INCLUDING NOVARTIS AND MERCK BUILD FEDERATED LEARNING PLATFORM FOR DRUG DISCOVERY

Venturebeat | September 17, 2020

Last June, 10 major pharmaceutical companies — Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). In partnership with Nvidia, Owkin, and other tech partners, the group sought to leverage techniques like federated learning to collectively train AI on datasets without having to share any pro...

Read More
news image

PREPARATION PRODUCTS OF YILING PHARMA APPROVED BY FDA FOR LAUNCH IN THE US MARKET

Yiling Pharmaceutical Co | September 19, 2020

Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter referred to as the "FDA"), which were submitted by Yiling Wanzhou International Pharmaceutical Co., Ltd., one of the wholly-owned subsidiaries of Yiling Pharmaceutical Co., Ltd., meaning that these products are approved to be produced and sold i...

Read More
news image

U.S. FDA ACCEPTS BIOHAVEN'S SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) OF NURTEC™ ODT FOR THE PREVENTIVE TREATMENT OF MIGRAINE

Biohaven Pharmaceutical Holding Company Ltd. | October 14, 2020

Biohaven Pharmaceutical Holding Company Ltd. today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) goal date for completion of the FDA review of the preventive sNDA is set for 2Q2021. Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "Patients with mi...

Read More